Anti-TNF continuation after 24 weeks of pregnancy beneficial to persons with IBD, does not affect neonatal outcomes

A 10-year emulation trial of pregnant persons with inflammatory bowel disease (IBD) has found that continuation of anti–tumor necrosis factor (anti-TNF) treatment after 24 weeks of pregnancy appears beneficial regarding IBD activity and prematurity, while not affecting neonatal outcomes and serious infections in the offspring. More than six million people in both North America and […]

Continue Reading